Register for the ESMO Post Show Roundtable
Highlights from the virtual conference
J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.
Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.
The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.